ENANTA PHARMACEUTICALS INC 4
4 · ENANTA PHARMACEUTICALS INC · Filed Mar 28, 2013
Insider Transaction Report
Form 4
AFTING ERNST-GUNTER
Director
Transactions
- Conversion
Common Stock
2013-03-26+97→ 21,072 total - Conversion
Common Stock
2013-03-26+11,215→ 32,287 total - Conversion
Series C Convertible Preferred Stock
2013-03-26−2,906→ 0 total→ Common Stock (674 underlying) - Conversion
Common Stock
2013-03-26+674→ 20,975 total - Conversion
Series G-2 Convertible Preferred Stock
2013-03-26−48,337→ 0 total→ Common Stock (11,215 underlying) - Conversion
Series B Convertible Preferred Stock
2013-03-26−10,000→ 0 total→ Common Stock (2,320 underlying) - Conversion
Series E Convertible Preferred Stock
2013-03-26−320→ 0 total→ Common Stock (97 underlying) - Conversion
Common Stock
2013-03-26+2,320→ 20,301 total - Conversion
Common Stock
2013-03-26+2,320→ 17,981 total - Conversion
Series A Convertible Preferred Stock
2013-03-26−10,000→ 0 total→ Common Stock (2,320 underlying)
Footnotes (5)
- [F1]The Series A Convertible Preferred Stock has no expiration date, and each share of Series A Convertible Preferred Stock converted automatically into approximately 0.23202 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.
- [F2]The Series B Convertible Preferred Stock has no expiration date, and each share of Series B Convertible Preferred Stock converted automatically into approximately 0.23202 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.
- [F3]The Series C Convertible Preferred Stock has no expiration date, and each share of Series C Convertible Preferred Stock converted automatically into approximately 0.23202 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.
- [F4]The Series E Convertible Preferred Stock has no expiration date, and each share of Series E Convertible Preferred Stock converted automatically into approximately 0.30529 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.
- [F5]The Series G-2 Convertible Preferred Stock has no expiration date, and each share of Series G-2 Convertible Preferred Stock converted automatically into approximately 0.23202 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.